Seven-year outcomes following intensive anti-vascular endothelial growth factor therapy in patients with exudative age-related macular degeneration

BACKGROUND: Anti-vascular endothelial growth factor (VEGF) therapy is currently the most effective therapy of exudative age-related macular degeneration (AMD). The aim of this study was to assess long-term benefits of intensive aflibercept and ranibizumab anti-VEGF therapy in patients with exudative...

Descripción completa

Detalles Bibliográficos
Autores principales: Lukacs, Regina, Schneider, Miklos, Nagy, Zoltan Zsolt, Sandor, Gabor Laszlo, Kaan, Kinga, Asztalos, Antonia, Enyedi, Lajos, Pek, Gyorgy, Barcsay, Gyorgy, Szabo, Antal, Borbandy, Agnes, Kovacs, Illes, Resch, Miklos Denes, Papp, Andras
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022151/
https://www.ncbi.nlm.nih.gov/pubmed/36932356
http://dx.doi.org/10.1186/s12886-023-02843-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10022151/
https://www.ncbi.nlm.nih.gov/pubmed/36932356
http://dx.doi.org/10.1186/s12886-023-02843-2

Ejemplares similares